Search clinical trials for: Drug: salmeterol xinafoate

Total 254213 results

Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone Salmeterol Xinafoate vs. ADVAIR DISKUS® in Healthy Volunteers (BREATH-PK500)

Bioequivalence

Greece
Neothetics, Inc

Completed

Dose-ranging Study (LIPO-102-CL-11)

Abdominal Contour Defects

United States
Neothetics, Inc

Completed

Dose Ranging Study (RESET)

Periumbilical Subcutaneous Adipose Tissue Reduction

United States
GlaxoSmithKline

Completed

ROTAHALER Device Optimization Study

Asthma

Australia
GlaxoSmithKline

Completed

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg Twice Daily To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg Twice Daily In Symptomatic Patients With Asthma

Asthma

United States, Argentina, Philippines, Canada, Brazil
GlaxoSmithKline

Completed

Study Of Asthma And Genetics In Patients To Be Treated With Fluticasone Propionate/Salmeterol Or Salmeterol Xinafoate

Asthma

United States, Peru, Kenya, Puerto Rico
GlaxoSmithKline

Withdrawn

A Study in Patients With Moderate Asthma to Compare Pharmacokinetics and Pharmacodynamic Effects of Fluticasone Propionate and Salmeterol Delivered Via the ROTAHALER® Inhaler Relative to the DISKUS® Inhaler

Asthma
Mylan Pharma UK Ltd.

Completed

MGR001 / Advair Diskus Local Equivalence Study in Asthma

Asthma

United States
Neothetics, Inc

Completed

Study to Evaluate the Safety and Efficacy of LIPO-202 for the Reduction of Submental Subcutaneous Fat

Submental Fat

United States
GlaxoSmithKline

Completed

Clinical Evaluation Of GW815SF For Chronic Obstructive Pulmonary Disease (Chronic Bronchitis, Emphysema)

Pulmonary Disease, Chronic Obstructive

Japan
Boehringer Ingelheim

Terminated

Tiotropium/Salmeterol Inhalation Powder in COPD

Pulmonary Disease, Chronic Obstructive

United States, Austria, Canada, Denmark, Estonia, Finland, France, Germany, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Netherlands, Slovakia, South Africa, Sweden
Boehringer Ingelheim

Terminated

Tiotropium/Salmeterol Inhalation Powder (Spiriva Handihaler and Salmeterol Polyethylene (PE) Capsule) in Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive

United States, Austria, Belgium, Canada, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Italy, Korea, Republic of, Latvia, Lithuania, Netherlands, Slovakia, Sweden
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Unknown

Salmeterol Xinafoate and Fluticasone Propinate Powder for Inhalation for Asthma

Asthma

China
Oriel Therapeutics

Completed

Clinical Efficacy Study of Salmeterol Xinafoate/Fluticasone Propionate in Asthma

Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Long-Term Safety Study of Fluticasone Propionate (Fp) Multidose Dry Powder Inhaler (MDPI) and Fluticasone Propionate/Salmeterol (FS) MDPI in Patients With Persistent Asthma

Persistent Asthma

United States
Teva Branded Pharmaceutical Products R&D, Inc.

Completed

Dose Ranging Study of the Salmeterol Component of Fluticasone /Salmeterol Spiromax Compared to Fluticasone Spiromax and Advair Diskus in Asthma Subjects

Asthma

United States
Novartis Pharmaceuticals

Not yet recruiting

A Study to Evaluate the Efficacy and Safety of QVM149 (Indacaterol Acetate / Glycopyrronium Bromide / Mometasone Furoate) Versus Salmeterol Xinafoate/Fluticasone Propionate in Children From 12 Years to Less Than 18 Years of Age With Asthma.

Asthma
Boehringer Ingelheim

Completed

Pharmacokinetics of Salmeterol Via HandiHaler® in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Pharmacokinetics of Salmeterol (Serevent®) After Inhalation With Metered Dose Inhaler (MDI) and Diskus® in Healthy Male Volunteers

Healthy
Boehringer Ingelheim

Completed

Efficacy, Pharmacokinetics and Safety Comparison of Salmeterol Inhalation Powder Administered Via the HandiHaler® 2 and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline

Terminated

Study In Asthma Control

Asthma

Canada
Arthur F Gelb MD

Completed

Evaluation Inhaled Corticosteroids on Exhaled Nitric Oxide Gas Exchange

COPD

United States
Boehringer Ingelheim

Completed

Salmeterol Inhalation Powder Administered as the Xinafoate Salt From Hard Polyethylene Capsules Via the HandiHaler® 2, and Serevent® Diskus® in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Different Doses of Indacaterol in Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease

United States
University of Copenhagen

Completed

Pharmacological Properties of Salmeterol

Pharmacokinetics in Healthy Young Men

Denmark
Intech Biopharm Ltd.

Completed

Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers With Charcoal Block

Asthma | Chronic Obstructive Pulmonary Disease (COPD)

Taiwan
GlaxoSmithKline

Completed

A 12-Month Study Comparing Fluticasone Propionate/Salmeterol (ADVAIR) DISKUS Combination Product 250/50mcg BID To Fluticasone Propionate (FLOVENT) DISKUS 250 mcg BID In Symptomatic Subjects With Asthma

Asthma

United States, Argentina, Canada, Philippines, Brazil
GlaxoSmithKline

Completed

Fluticasone Propionate-salmeterol Combination Adherence in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Pulmonary Disease, Chronic Obstructive
Intech Biopharm Ltd.

Completed

Bioequivalence Study of Synflutide HFA Inhaler and Seretide Evohaler in Healthy Volunteers Without Charcoal Block

Asthma | Chronic Obstructive Pulmonary Disease (COPD)

Taiwan
Boehringer Ingelheim

Completed

Efficacy and Safety of Tiotropium and Salmeterol in Moderate Persistent Asthma Patients Homozygous for B16-Arg/Arg

Asthma

Austria, Belgium, Denmark, Finland, France, Germany, Greece, Italy, Russian Federation, Slovakia, South Africa, Spain, Turkey, United Kingdom
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Recruiting

Bioequivalence Study for Fluticasone Propionate 500 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers

Bioequivalence

Greece
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Pivotal Bioequivalence Study Between Fluticasone Propionate 500 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 500/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
GlaxoSmithKline

Completed

Chronic Obstructive Pulmonary Disease (COPD) Post-hospitalization Study

Pulmonary Disease, Chronic Obstructive

United States, Argentina, Norway
Novartis Pharmaceuticals

Completed

Efficacy and Safety of Different Doses of Indacaterol

Asthma

United States
Brigham and Women's Hospital

Completed

How Different Beta-2 Receptor Genotypes Affect an Asthmatic's Response to Regular Salmeterol Treatment (SECS)

Asthma

United States
Bispebjerg Hospital
Hormone Laboratory, Aker University Hospital, Oslo, Norway

Unknown

Concentrations of Salmeterol in Blood and Urine

Asthma

Denmark
Università degli Studi di Ferrara
GlaxoSmithKline

Completed

Effects of Inhaled Corticosteroids on Sputum Bacterial Load in COPD

Chronic Obstructive Pulmonary Disease

Italy
Novartis

Completed

Efficacy and Safety of Indacaterol in Patients With Chronic Obstructive Pulmonary Disease (COPD) Using Salmeterol as Active Control

Chronic Obstructive Pulmonary Disease (COPD)

Russian Federation, Germany, Denmark, Italy, Canada, Czech Republic, Hungary, India, Slovakia, France, Colombia, Finland, Taiwan, Iceland, Peru
Novartis

Completed

Study of Indacaterol Dosed in the Evening in Patients With Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

Germany, Spain, France
GlaxoSmithKline

Completed

Effects of Salmeterol on Autonomic Nervous System (ESAN)

Pulmonary Disease, Chronic Obstructive

Germany
GlaxoSmithKline

Withdrawn

Shortness Of Breath Questionnaire Validation Study

Pulmonary Disease, Chronic Obstructive
GlaxoSmithKline

Completed

SERETIDE 100/50 bd (Twice Daily) Versus FLIXOTIDE 100 bd As Initial Maintenance Therapy In Moderate Asthma In Adults

Asthma
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Completed

A Bioequivalence Study Between Fluticasone Propionate 250 mcg and Salmeterol Xinafoate 50 mcg Inhalation Powder/Respirent Pharmaceuticals vs. ADVAIR DISKUS® 250/50 Inhalation Powder/GSK in Healthy Volunteers

Bioequivalence

Greece
University of Dundee

Completed

Fluticasone/Salmeterol (FP/SM) Versus Double the Dose Fluticasone (FP) in Patients With Mild to Moderate Asthma (CLE001)

Asthma

United Kingdom
GlaxoSmithKline

Completed

Advair® DISKUS® Versus Serevent® DISKUS® For Chronic Obstructive Pulmonary Disease Exacerbations

Pulmonary Disease, Chronic Obstructive

United States, Canada
Novartis Pharmaceuticals

Completed

Safety of Indacaterol in Patients (≥ 12 Years) With Moderate to Severe Persistent Asthma

Asthma

Germany, Spain, United States, Turkey, Canada, Hungary, Slovakia, Italy, Argentina, Czech Republic, France, Peru
Novartis Pharmaceuticals

Completed

Safety and Efficacy of Indacaterol Once Daily Versus Salmeterol Twice Daily in Chronic Obstructive Pulmonary Disease (COPD) (INSIST)

Chronic Obstructive Pulmonary Disease (COPD)

United States, Germany, Spain, Turkey, Hungary, Czech Republic, India, Slovakia
Boehringer Ingelheim

Completed

Efficacy and Safety Comparison of Tiotropium Daily + Salmeterol Daily or Twice Daily Versus Tiotropium Daily in Patients With COPD

Pulmonary Disease, Chronic Obstructive

Germany
GlaxoSmithKline

Completed

Outcomes for Medicare Asthma Patients Taking Fluticasone Propionate/Salmeterol Xinafoate Combination Versus Inhaled Corticosteroids or Other Combination Therapy

Asthma
Respirent Pharmaceuticals Co Ltd.
Becro Ltd.

Active, not recruiting

Bioequivalence Study for Fluticasone Propionate 100 mcg/Salmeterol Xinafoate 50 mcg Inhalation Powder in Healthy Volunteers

Bioequivalence

Greece

3

Subscribe